NewInsight: Anthropic's IPO price against 48 tech IPOs since 1997

Evommune EVMN

Evommune listed on NYSE on 6 Nov 2025 and is not in the S&P 500. It is worth $299 million. Its price history starts on 7 Nov 2025. Its board has 9 directors, 6 of them independent. 4 other officers are on file. At 30 Jun 2026, Eqt Fund Management S.a r.l. was its largest institutional holder, with 14.7% of the company.

CEO
Luis C. Pena
Chair
Benjamin F. McGraw, III, Pharma. D.
Listed
6 Nov 2025 on NYSE
Headquarters
Palo Alto, CA
Market cap
$299M
19 Nov 2026 close
Revenue
$13M
Fiscal year 2025
Price to sales
23.0
Market cap over revenue

Financials

Financial history

Twelve months to 30 Sep 2025, from Evommune's quarterly filings.

Quarters since Mar 2025

P/E
-
No profit over the last four quarters

Quarterly results

Each quarter's revenue, net income and free cash flow.

Mar 2025 to Sep 2025

Not reported for enough quarters.

Evommune's market cap since November 2025

Marked weeks are changes in the share count, such as a merger, not market moves.

Weekly, up to 13 Nov 2026

Jan 2026MarMayJulSepNov$320M

Board and leadership

Board and officers

Board from the proxy filed 21 Apr 2026; officers filed up to 30 Sep 2026

NameTitleSinceIndependentCommitteesAge
Directors (9)
Benjamin F. McGraw, III, Pharma. D.ChairIndependent 路 since 2020 路 Audit, Compensation (chair), Nominating and Corporate Governance, Science and TechnologyExecutive Chairman, Perfuse TherapeuticsOther boards: Aerie PharmaceuticalsChair2020YesAudit, Compensation (chair), Nominating and Corporate Governance, Science and Technology77
Luis C. PenaPresident & CEONot independent 路 since 2020 路 Nominating and Corporate GovernancePresident & CEO2020NoNominating and Corporate Governance63
Eugene BauerChief Medical OfficerNot independent 路 since 2020 路 Science and TechnologyChief Medical Officer2020NoScience and Technology83
David E. CohenDirectorIndependent 路 since 2020 路 Compensation, Nominating and Corporate Governance (chair), Science and Technology (chair)Charles C. and Dorothea E. Harris Professor of Dermatology, Vice Chairman of Clinical Affairs, Chief of Allergy and Contact Dermatitis and Director of Occupational and Environmental Dermatology, New York University School of MedicineDirector2020YesCompensation, Nominating and Corporate Governance (chair), Science and Technology (chair)61
Derek DiRocco, Ph.D.DirectorIndependent 路 since 2024 路 Audit, Science and TechnologyPartner, RA Capital ManagementOther boards: 89Bio, Mineralys, Werewolf Therapeutics and Acrivon TherapeuticsDirector2024YesAudit, Science and Technology45
Arthur S. KirschDirectorIndependent 路 since 2025 路 Audit (chair), CompensationConsultant, Alvarez & MarsalOther boards: Liquidia Corporation and Atea PharmaceuticalsDirector2025YesAudit (chair), Compensation74
Benjamin F. McGraw IIIDirectorDirector
Rob Hopfner, R.Ph., Ph.D.DirectorIndependent 路 since 2020 路 Audit, Science and TechnologyManaging Partner, Pivotal bioVenture PartnersDirector2020YesAudit, Science and Technology53
Felice Isabel Verduyn-van WeegenDirectorIndependent 路 since 2021 路 Nominating and Corporate Governance, Science and TechnologyPartner, EQTDirector2021YesNominating and Corporate Governance, Science and Technology39
Officers (4)
Kyle CarverChief Financial OfficerLast filed 10 Jul 2026Chief Financial Officer
Janice Suzann DrewChief of Dev. OperationsLast filed 24 Jun 2026Chief of Dev. Operations
Gregory S. MossChief Business & Legal OfficerLast filed 1 Jun 2026Chief Business & Legal Officer
Jeegar Pravinkumar PatelChief Scientific OfficerLast filed 24 Jun 2026Chief Scientific Officer

Owners and trading

Largest institutional holders

Each fund group's share of Evommune. Where a company has several share classes, the share is of its total value. Stakes are of the shares out at 30 Jun 2026; the count has since grown 15%.

13F filings for the quarter to 30 Jun 2026

  • Eqt Fund Management S.a r.l.14.7%
  • Ra Capital Management9.7%
  • T. Rowe Price5.4%
  • Pivotal bioVenture Partners Investment Advisor5.3%
  • JPMorgan4.3%

These five hold 39.4% of Evommune.

Insider trades

Open-market buys and sales by directors and officers. Grants, option exercises and shares withheld for tax are left out.

Trades from 19 Nov 2025 to 19 Nov 2026

Directors and officers sold $2.3 million of stock in 8 sales and bought $163,610 in 3 purchases in the 12 months to 19 Nov 2026.

DatePersonTitleTypeSharesValue
8 Jul 2026BuyKyle CarverChief Financial OfficerChief Financial OfficerBuy1,000$13K
7 Jul 2026BuyArthur S. KirschDirectorDirectorBuy10,000$133K
22 Jun 2026SaleJanice Suzann DrewChief of Dev. OperationsChief of Dev. OperationsSale20,000$453K
22 Jun 2026SaleLuis C. PenaPresident & CEOPresident & CEOSale7,438$169K
22 Jun 2026SaleJeegar Pravinkumar PatelChief Scientific OfficerChief Scientific OfficerSale1,488$33K
2 Jun 2026SaleDavid E. CohenDirectorDirectorSale6,056$123K
1 Jun 2026SaleLuis C. PenaPresident & CEOPresident & CEOSale16,787$382K
1 Jun 2026SaleJeegar Pravinkumar PatelChief Scientific OfficerChief Scientific OfficerSale16,687$379K
28 May 2026SaleKyle CarverChief Financial OfficerChief Financial OfficerSale18,175$415K
28 May 2026SaleGregory S. MossChief Business & Legal OfficerChief Business & Legal OfficerSale14,223$325K

Showing 10 of 11 trades

Timeline

Leadership changes, layoffs and insider sales

20 Nov 2024 to 20 Nov 2026; insider sales from 19 Nov 2025

1 large insider sale in the last two years.

Left the company or board 0Appointed 0WARN layoff notices 0Large insider sales 1Jan 2025AprJulOctJan 2026AprJulOct

Insider sales of $1 million or more, and the largest tenth of Evommune's insider sales.

Events, newest first

Not on file: no trades disclosed by members of Congress or officials since November 2023, no WARN layoff notices under its own name or a listed subsidiary's since November 2023, no open roles from its careers site yet and no earnings release figures from the last six months.